The phase 2 trial – dubbed BNT111-01 – is enrolling 120 patients and will compare the combination to each of the drugs given alone, and is due to complete in mid-2022. Meanwhile, BioNTech ...

I am deeply troubled by the growing distrust of science in our society, just at the time when its insights are most needed.

Responding to rising mpox cases in Africa, the World Health Organization declared a public health emergency of international ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech ... during the coming 2022/23 flu season in the northern hemisphere.

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...

The world may need new COVID-19 vaccines by mid-2022 to protect against coronavirus mutations, BioNTech CEO Ugur Sahin told the Financial Times on Sunday. But future variants of the virus could ...

In this June 25, 2022, file photo, the FDA White Oak Campus ... The updated vaccines from Pfizer-BioNTech and Moderna will be available for those 6 months old and older Vaccine manufacturers ...

Catching the virus that causes COVID-19 or getting a COVID-19 vaccination gives you protection, also called immunity, from the virus. But over time, that protection seems to ...

San Diego, California-based Maravai (MRVI), which provides technology for mRNA vaccine manufacturing, generated more than 60% of its revenue from Pfizer (PFE) and BioNTech (BNTX) in 2022.

The FDA issued Emergency Use Authorization for the Pfizer-BioNTech vaccine on Dec. 11, 2020, and for the Moderna vaccine on Dec. 18, 2020 for those 18 and older. Novavax was approved June 7, 2022 ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...